Carteolol

Summary

Carteolol (CHEMBL839) is an approved small-molecule β-adrenergic antagonist (ATC S01ED05); indicated across 2 conditions including cardiovascular disorder and glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01ED05 (+2 more)
• Indications: 2 conditions
• Chemistry: 292.37 Da · C16H24N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL839
Name	Carteolol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2583
ChEBI	CHEBI:3437
ATC	S01ED05, C07AA15, S01ED55
Molecular formula	C16H24N2O3
Molecular weight	292.37
InChIKey	LWAFSWPYPHEXKX-UHFFFAOYSA-N

SMILES: CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O

IUPAC name: 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one

Pharmacological roles (ChEBI): β-adrenergic antagonist, antihypertensive agent, antiglaucoma drug, anti-arrhythmia drug, sympatholytic agent.

Also known as: Carteolol, carteolol, CARTEOLOL, Carteolol hydrochloride

Parent form; salt/anhydrous children: CHEMBL1201002

Patent coverage: 4,431 distinct patent families (18,411 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 18,400 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB1	9	AC50	1	nM	CHEMBL_ACT_25122275
ADRB1	8.72	Ki	1.9	nM	CHEMBL_ACT_113155
ADRB2	8.22	AC50	6	nM	CHEMBL_ACT_25123284
HTR1A	5.06	AC50	8800	nM	CHEMBL_ACT_25216374

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).